Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $95,052.63 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Anil P. Ranganath sold 703 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $135.21, for a total value of $95,052.63. Following the completion of the sale, the insider now owns 8,809 shares of the company’s stock, valued at $1,191,064.89. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

TransMedics Group Stock Up 0.6 %

Shares of NASDAQ TMDX opened at $162.89 on Monday. The company has a market cap of $5.43 billion, a price-to-earnings ratio of -479.09 and a beta of 1.99. The company has a current ratio of 9.37, a quick ratio of 8.76 and a debt-to-equity ratio of 2.67. TransMedics Group, Inc. has a 12 month low of $36.42 and a 12 month high of $171.98. The stock has a 50-day moving average price of $145.56 and a two-hundred day moving average price of $114.01.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. The business had revenue of $114.30 million during the quarter, compared to analysts’ expectations of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The firm’s quarterly revenue was up 117.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.03) EPS. As a group, analysts forecast that TransMedics Group, Inc. will post 1.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TMDX. SG Americas Securities LLC acquired a new stake in shares of TransMedics Group during the 4th quarter valued at $204,000. Raymond James & Associates raised its position in TransMedics Group by 22.7% in the fourth quarter. Raymond James & Associates now owns 4,593 shares of the company’s stock valued at $363,000 after purchasing an additional 851 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its position in TransMedics Group by 47.0% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 17,252 shares of the company’s stock valued at $1,362,000 after purchasing an additional 5,515 shares during the last quarter. Mackenzie Financial Corp acquired a new stake in shares of TransMedics Group during the fourth quarter valued at about $35,804,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of TransMedics Group by 7.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,396 shares of the company’s stock worth $584,000 after purchasing an additional 483 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TMDX has been the subject of a number of recent analyst reports. TD Cowen upped their target price on TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, June 7th. Cantor Fitzgerald initiated coverage on shares of TransMedics Group in a research report on Thursday, June 6th. They set an “overweight” rating and a $161.00 price objective for the company. JPMorgan Chase & Co. increased their price objective on shares of TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. Piper Sandler boosted their target price on shares of TransMedics Group from $170.00 to $180.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Finally, Stephens increased their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and an average target price of $166.88.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.